324 related articles for article (PubMed ID: 10571610)
1. Eradication of Helicobacter pylori does not decrease the long-term use of acid-suppressive medication.
Tan AC; Hartog GD; Mulder CJ
Aliment Pharmacol Ther; 1999 Nov; 13(11):1519-22. PubMed ID: 10571610
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Hong EJ; Park DI; Oh SJ; Song MJ; Choi WH; Hong CH; Park JH; Kim HJ; Cho YK; Shon CI; Jeon WK; Kim BI
Korean J Gastroenterol; 2008 Aug; 52(2):80-5. PubMed ID: 19077498
[TBL] [Abstract][Full Text] [Related]
3. Helicobacter pylori eradication in patients on long-term H2 receptor antagonists. Economic and symptomatic benefits. A large prospective study in primary care.
Verma S; Giaffer MH
Helicobacter; 2002 Apr; 7(2):91-8. PubMed ID: 11966867
[TBL] [Abstract][Full Text] [Related]
4. [Are proton pump inhibitors superior to H2 receptor antagonists within the scope of H. pylori eradication therapy? Meta analysis of current parallel group comparisons].
Holtmann G; Layer P; Goebell H
Z Gastroenterol; 1996 May; 34(5):267-72. PubMed ID: 8686357
[TBL] [Abstract][Full Text] [Related]
5. Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer.
Hu FL; Jia JC; Li YL; Yang GB
J Int Med Res; 2003; 31(6):469-74. PubMed ID: 14708410
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study).
Treiber G; Wittig J; Ammon S; Walker S; van Doorn LJ; Klotz U
Arch Intern Med; 2002 Jan; 162(2):153-60. PubMed ID: 11802748
[TBL] [Abstract][Full Text] [Related]
7. Low yield of endoscopy in patients with persistent dyspepsia taking proton pump inhibitors.
Smith T; Verzola E; Mertz H
Gastrointest Endosc; 2003 Jul; 58(1):9-13. PubMed ID: 12838213
[TBL] [Abstract][Full Text] [Related]
8. Helicobacter pylori eradication ameliorates symptoms and improves quality of life in patients on long-term acid suppression. A large prospective study in primary care.
Verma S; Giaffer MH
Dig Dis Sci; 2002 Jul; 47(7):1567-74. PubMed ID: 12141818
[TBL] [Abstract][Full Text] [Related]
9. Successful eradication of Helicobacter pylori prevents relapse of peptic ulcer disease.
Tomita T; Fukuda Y; Tamura K; Tanaka J; Hida N; Kosaka T; Hori K; Sakagami T; Satomi M; Shimoyama T
Aliment Pharmacol Ther; 2002 Apr; 16 Suppl 2():204-9. PubMed ID: 11966543
[TBL] [Abstract][Full Text] [Related]
10. [Prevention of bleeding recurrence in peptic ulcer by Helicobacter pylori eradication].
Gisbert JP
Gastroenterol Hepatol; 2005 Nov; 28(9):567-75. PubMed ID: 16277966
[No Abstract] [Full Text] [Related]
11. The changing role of H2-receptor antagonists in acid-related diseases.
Lamers CB
Eur J Gastroenterol Hepatol; 1996 Oct; 8 Suppl 1():S3-7. PubMed ID: 8930573
[TBL] [Abstract][Full Text] [Related]
12. Helicobacter pylori eradication for peptic ulceration: an observational study in a Scottish primary care setting.
Forrest EH; MacKenzie JF; Stuart RC; Morris AJ
Scott Med J; 2002 Apr; 47(2):28-33. PubMed ID: 12058660
[TBL] [Abstract][Full Text] [Related]
13. Decision analysis of histamine H2-receptor antagonist maintenance therapy versus Helicobacter pylori eradication therapy: a randomised controlled trial in patients with continuing pain after duodenal ulcer.
Tavakoli M; Prach AT; Malek M; Hopwood D; Senior BW; Murray FE
Pharmacoeconomics; 1999 Oct; 16(4):355-65. PubMed ID: 10623364
[TBL] [Abstract][Full Text] [Related]
14. Reappraisal of non-invasive management strategies for uninvestigated dyspepsia: a cost-minimization analysis.
Ladabaum U; Chey WD; Scheiman JM; Fendrick AM
Aliment Pharmacol Ther; 2002 Aug; 16(8):1491-501. PubMed ID: 12182749
[TBL] [Abstract][Full Text] [Related]
15. Age-dependent eradication of Helicobacter pylori with dual therapy.
Treiber G; Ammon S; Klotz U
Aliment Pharmacol Ther; 1997 Aug; 11(4):711-8. PubMed ID: 9305480
[TBL] [Abstract][Full Text] [Related]
16. [The attitude of primary health care physicians in the metropolitan area of Barcelona about the diagnosis and treatment of Helicobacter pylori infection in gastroduodenal diseases].
Martínez-Sánchez G; Saperas E; Benavent J; Mearin F; Piñol JL; Barenys M; Mascort JJ; Forné M; Bordas JM; Azagra R; Piqué JM
Gastroenterol Hepatol; 1998 Dec; 21(10):473-8. PubMed ID: 9927791
[TBL] [Abstract][Full Text] [Related]
17. Helicobacter pylori eradication therapy for functional dyspepsia: Systematic review and meta-analysis.
Du LJ; Chen BR; Kim JJ; Kim S; Shen JH; Dai N
World J Gastroenterol; 2016 Mar; 22(12):3486-95. PubMed ID: 27022230
[TBL] [Abstract][Full Text] [Related]
18. Effect of Helicobacter pylori eradication therapy on risk of hospitalization for a major ulcer event.
Hsiao FY; Tsai YW; Wen YW; Kuo KN; Tsai CR; Huang WF
Pharmacotherapy; 2011 Mar; 31(3):239-47. PubMed ID: 21361733
[TBL] [Abstract][Full Text] [Related]
19. Therapy for peptic ulcer disease.
Lukáš M
Vnitr Lek; 2018; 64(6):595-599. PubMed ID: 30223656
[TBL] [Abstract][Full Text] [Related]
20. Arrest of chronic acid suppressant drug use after successful Helicobacter pylori eradication in patients with peptic ulcer disease: a six-month follow-up study.
Hurenkamp GJ; Grundmeijer HG; Van Der Ende A; Tytgat GN; Assendelft WJ; Van Der Hulst RW
Aliment Pharmacol Ther; 2001 Jul; 15(7):1047-54. PubMed ID: 11421881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
